Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy.

Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, Welch M.

Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1206-11.


Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ.

Cancer Res. 2003 Sep 1;63(17):5496-504.


Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Mori T, Yoshii H, Asai T, Okazawa H, Welch MJ, Fujibayashi Y.

Nucl Med Biol. 2011 Feb;38(2):151-7. doi: 10.1016/j.nucmedbio.2010.08.009. Epub 2010 Oct 27.


Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection.

Yoshii Y, Matsumoto H, Yoshimoto M, Furukawa T, Morokoshi Y, Sogawa C, Zhang MR, Wakizaka H, Yoshii H, Fujibayashi Y, Saga T.

PLoS One. 2014 Jan 22;9(1):e86996. doi: 10.1371/journal.pone.0086996. eCollection 2014.


Basic characterization of 64Cu-ATSM as a radiotherapy agent.

Obata A, Kasamatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyohara J, Asai T, Welch MJ, Adams SG, Saji H, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2005 Jan;32(1):21-8. Erratum in: Nucl Med Biol. 2005 Jul;32(5):559.


Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, Sadato N, Sugimoto K, Itoh H.

Ann Nucl Med. 2000 Oct;14(5):323-8.


Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.


Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.

Clausen MM, Hansen AE, Lundemann M, Hollensen C, Pommer T, Munck Af Rosenschöld P, Kristensen AT, Kjær A, McEvoy FJ, Engelholm SA.

Radiat Oncol. 2014 Oct 16;9:228. doi: 10.1186/s13014-014-0228-0.


Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM.

J Nucl Med. 2013 Jul;54(7):1106-12. doi: 10.2967/jnumed.112.111120. Epub 2013 May 22.


Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model.

Connett JM, Buettner TL, Anderson CJ.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3207s-3212s.


Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ.

J Nucl Med. 2001 Apr;42(4):655-61.


In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50. Epub 2003 Apr 12.


Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Bradshaw TJ, Yip S, Jallow N, Forrest LJ, Jeraj R.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):399-405. doi: 10.1016/j.ijrobp.2014.02.016. Epub 2014 Mar 28.


Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.


Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS.

Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001.


Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

McCall KC, Humm JL, Bartlett R, Reese M, Carlin S.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9. doi: 10.1016/j.ijrobp.2012.05.005. Epub 2012 Jun 23.


Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells.

Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y.

Ann Nucl Med. 2001 Dec;15(6):499-504.


Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC.

Nucl Med Biol. 2005 Aug;32(6):623-30.


Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, Yoshii H, Oh M, Asai T, Okazawa H, Welch MJ, Fujibayashi Y.

Nucl Med Biol. 2010 May;37(4):395-404. doi: 10.1016/j.nucmedbio.2009.12.011. Epub 2010 Feb 10.


Supplemental Content

Support Center